Bifidobacterium longum ： Irritable Bowel Syndrome (IBS)
B エビデンス 少なくとも1件のランダム化試験がこれを支持しており、おおむね一貫した結果が得られています。RCTs demonstrate significant reduction in IBS composite symptom score versus placebo. Particular benefit for bloating and abdominal distension. Marketed as Alflorex/Align.
<\/script>\n`;
},
get iframeSnippet() {
const domain = 'gutcited.com';
const params = 'ingredient\u003Dbifidobacterium\u002Dlongum\u0026condition\u003Dibs';
return ``;
},
get activeSnippet() {
return this.method === 'script' ? this.scriptSnippet : this.iframeSnippet;
},
copySnippet() {
navigator.clipboard.writeText(this.activeSnippet).then(() => {
this.copied = true;
setTimeout(() => { this.copied = false; }, 2000);
});
}
}"
@keydown.escape.window="open = false"
@click.outside="open = false">
B
結論
RCTs demonstrate significant reduction in IBS composite symptom score versus placebo. Particular benefit for bloating and abdominal distension. Marketed as Alflorex/Align.
Key Study Findings
Meta-Analysis
n=3154
Comparative effectiveness and safety of probiotics with psychotropic potential in mental health benefits in irritable …
Dose: None
vs: placebo
Outcome: quality of life, depression, and anxiety in IBS …
効果: SUCRA=89.7% (B. longum for QoL); SUCRA=95.6% (probiotic combo for depression)
None
対象集団: patients with irritable bowel syndrome
Meta-Analysis
Strain-Specific Systematic Review with Meta-Analysis of Probiotics Efficacy in the Treatment of Irritable Bowel Syndrome.
Dose: None
vs: placebo
Outcome: improvement in key IBS symptoms
効果: None
None
対象集団: patients with IBS from 32 RCTs evaluating 10 probiotic strains
Controlled Clinical Trial
n=51
12 weeks
Open-label
Targeted probiotic therapy in irritable bowel syndrome: a clinical evaluation on Clostridium butyricum CBM588 and …
Dose: None
vs: Pre-treatment baseline
Outcome: IBS-SSS score reduction
効果: None
None
対象集団: IBS-D and IBS-C patients
Observational Study
n=37
8 weeks
Open-label
An 8-Week Course of Bifidobacterium longum 35624® Is Associated with a Reduction in the Symptoms …
Dose: None
vs: None
Outcome: Total IBS symptom score (TISS)
効果: 43.4% TISS reduction; >60% >=30% responders
None
対象集団: Adults with IBS (Rome IV criteria)
In Vitro
n=35
A Probiotic Mixture of Lactobacillus rhamnosus LR 32, Bifidobacterium lactis BL 04, and Bifidobacterium longum …
Dose: 1e6 CFU/mL
vs: IBS supernatants without probiotic
Outcome: Caco-2 paracellular permeability
効果: None
<0.001
対象集団: IBS patients (28) and asymptomatic controls (7)
Review
The Role and the Regulation of NLRP3 Inflammasome in Irritable Bowel Syndrome: A Narrative Review.
Dose: None
vs: None
Outcome: IBS symptom management via NLRP3 inhibition
効果: None
None
対象集団: Patients with IBS (narrative review)
Key Statistics
4
研究数
600
参加者数
↑
Positive
B
グレード
Referenced Papers
European journal of …
2026
Journal of clinical …
2026
An 8-Week Course of Bifidobacterium longum 35624® Is Associated with a Reduction in the Symptoms of Irritable Bowel Syndrome.
Observational
Probiotics and antimicrobial …
2025
6 件の引用
The Role and the Regulation of NLRP3 Inflammasome in Irritable Bowel Syndrome: A Narrative Review.
Review
Microorganisms
2025
4 件の引用
International journal of …
2025
4 件の引用
Frontiers in medicine
2025
3 件の引用
Gut microbes
2024
22 件の引用
Nutrients
2024
13 件の引用
Microbiology spectrum
2024
9 件の引用
Journal of neurogastroenterology …
2024
4 件の引用
Journal of clinical …
2024
4 件の引用
Effects of Bifidobacterium longum 35624 in Children and Adolescents with Irritable Bowel Syndrome.
Other
Nutrients
2024
4 件の引用
Gut microbes
2024
Journal of translational …
2023
30 件の引用
Food & function
2023
18 件の引用
Neurogastroenterology and motility
2023
16 件の引用
Journal of gastroenterology …
2023
11 件の引用
Terapevticheskii arkhiv
2023
3 件の引用
Voprosy pitaniia
2023
Effect of Bifidobacterium longum 35624 on disease severity and quality of life in patients with irritable bowel syndrome.
Observational
World journal of …
2022
27 件の引用
Journal of neurogastroenterology …
2022
21 件の引用
Journal of microbiology …
2022
15 件の引用
Computational and structural …
2022
15 件の引用
Scientific reports
2022
14 件の引用
Terapevticheskii arkhiv
2022
6 件の引用
Microorganisms
2021
47 件の引用
Nutrients
2021
36 件の引用
Clinical nutrition ESPEN
2021
11 件の引用
Voprosy pitaniia
2021
3 件の引用
Gastroenterology
2020
290 件の引用
European journal of …
2020
80 件の引用
Nutrients
2020
78 件の引用
Nutrients
2020
59 件の引用
Gut microbes
2020
36 件の引用
Journal of clinical …
2020
31 件の引用
The Cochrane database …
2020
14 件の引用
Nutrients
2019
114 件の引用
Beneficial microbes
2019
31 件の引用
Journal of neurogastroenterology …
2018
121 件の引用
Saudi journal of …
2018
41 件の引用
Effectiveness of Probiotics in Children With Functional Abdominal Pain Disorders and Functional Constipation: A Systematic Review.
Systematic Review
Journal of clinical …
2018
34 件の引用
Gastroenterology
2018
23 件の引用
Gastroenterology
2017
684 件の引用
The Australian and …
2017
280 件の引用
Efficacy of Bifidobacterium infantis 35624 in patients with irritable bowel syndrome: a meta-analysis.
Meta-Analysis
Current medical research …
2017
86 件の引用
Journal of gastroenterology …
2017
32 件の引用
Current medical research …
2017
21 件の引用
PloS one
2016
83 件の引用
Artificial cells, nanomedicine, …
2016
16 件の引用
Journal of gastroenterology …
2014
164 件の引用
Orvosi hetilap
2014
6 件の引用
Effect of probiotic species on irritable bowel syndrome symptoms: A bring up to date meta-analysis.
Meta-Analysis
Revista espanola de …
2013
102 件の引用
Journal of clinical …
2012
207 件の引用
Acta bio-medica : …
2006
41 件の引用
Dosage & Usage
mg = milligrams · mcg = micrograms (1,000× smaller) · IU = International Units
一般的な使用量
- general:
- 1-10 billion CFU/day
- ibssupport:
- 1 billion CFU/day (35624 strain, marketed as Alflorex/Align)
上限量： Well-tolerated up to 10 billion CFU/day in clinical trials
研究で検討された用量
| 用量 | 期間 | 効果 | N |
|---|---|---|---|
| None | -- | Positive | 3154 |
| None | -- | Positive | -- |
| None | 12 weeks | Positive | 51 |
| None | 8 weeks | Positive | 37 |
| 1e6 CFU/mL | -- | Positive | 35 |
| None | -- | Positive | -- |
| None | 12 weeks | Positive | -- |
| 1x10^10 CFU daily | 6 weeks | Positive | 35 |
推奨摂取タイミング： On an empty stomach or before meals
Safety & Side Effects
報告されている副作用
- ⚠ Mild gas and bloating during initial use
- ⚠ Occasional abdominal discomfort
- ⚠ Rare loose stools
- ⚠ Very rare: bacteremia in immunocompromised individuals
既知の相互作用
- ● Antibiotics (may reduce probiotic viability; space dosing 2 hours apart)
- ● Immunosuppressants (use with caution in immunocompromised patients)
耐容上限摂取量： Well-tolerated up to 10 billion CFU/day in clinical trials
サプリメントの摂取を開始する前に、必ず医療専門家にご相談ください。
Frequently Asked Questions
Does Bifidobacterium longum help with Irritable Bowel Syndrome (IBS)?
Based on 4 studies with 600 participants, there is moderate evidence from clinical studies that Bifidobacterium longum may support Irritable Bowel Syndrome (IBS) management. Our evidence grade is B (Good Evidence).
How much Bifidobacterium longum should I take for Irritable Bowel Syndrome (IBS)?
Studies have used various dosages. A commonly studied range is 1-10 billion CFU/day. Always consult your healthcare provider before starting any supplement regimen.
Are there side effects of Bifidobacterium longum?
Reported side effects may include Mild gas and bloating during initial use, Occasional abdominal discomfort, Rare loose stools, Very rare: bacteremia in immunocompromised individuals. Most side effects are mild and dose-dependent. Consult your doctor if you experience any adverse reactions.
How strong is the evidence for Bifidobacterium longum and Irritable Bowel Syndrome (IBS)?
We rate the evidence as Grade B (Good Evidence). This rating is based on 4 peer-reviewed studies with 600 total participants. The overall direction of effect is positive.
Related Evidence
に関する他の成分： Irritable Bowel Syndrome (IBS)
References
- [1] Theodore Rokkas et al.. Eur J Gastroenterol Hepatol. 2026. Comparative effectiveness and safety of probiotics with psychotropic potential in mental health benefits in irritable bowel syndrome: a systematic review … doi:10.1097/MEG.0000000000003062 PubMed
- [2] Roman Maslennikov et al.. J Clin Med. 2026. Strain-Specific Systematic Review with Meta-Analysis of Probiotics Efficacy in the Treatment of Irritable Bowel Syndrome. doi:10.3390/jcm15031152 PubMed
- [3] Marion Lenoir et al.. Probiotics Antimicrob Proteins. 2025. An 8-Week Course of Bifidobacterium longum 35624® Is Associated with a Reduction in the Symptoms of Irritable Bowel Syndrome. doi:10.1007/s12602-023-10151-w PubMed
- [4] Arezina Kasti et al.. Microorganisms. 2025. The Role and the Regulation of NLRP3 Inflammasome in Irritable Bowel Syndrome: A Narrative Review. doi:10.3390/microorganisms13010171 PubMed
- [5] Maria Raffaella Barbaro et al.. Int J Mol Sci. 2025. A Probiotic Mixture of Lactobacillus rhamnosus LR 32, Bifidobacterium lactis BL 04, and Bifidobacterium longum BB 536 Counteracts the Increase … doi:10.3390/ijms26062656 PubMed
- [6] Alexander Bertuccioli et al.. Front Med (Lausanne). 2025. Targeted probiotic therapy in irritable bowel syndrome: a clinical evaluation on Clostridium butyricum CBM588 and Bifidobacterium longum W11. doi:10.3389/fmed.2025.1604319 PubMed
- [7] Francois-Pierre Martin et al.. Gut Microbes. 2024. Metabolome-associated psychological comorbidities improvement in irritable bowel syndrome patients receiving a probiotic. doi:10.1080/19490976.2024.2347715 PubMed
- [8] Malwina Naghibi et al.. Nutrients. 2024. Effect of Postbiotic Bifidobacterium longum CECT 7347 on Gastrointestinal Symptoms, Serum Biochemistry, and Intestinal Microbiota in Healthy Adults: A Randomised, … doi:10.3390/nu16223952 PubMed
- [9] Guangyu Ma et al.. Microbiol Spectr. 2024. Effect of probiotic administration during pregnancy on the functional diversity of the gut microbiota in healthy pregnant women. doi:10.1128/spectrum.00413-24 PubMed
- [10] Young Hoon Chang et al.. J Neurogastroenterol Motil. 2024. Efficacy of Quadruple-coated Probiotics in Patients With Irritable Bowel Syndrome: A Randomized, Double-blind, Placebo-controlled, Parallel-group Study. doi:10.5056/jnm23036 PubMed
- [11] Anita Gąsiorowska et al.. J Clin Med. 2024. Efficacy and Safety of a Mixture of Microencapsulated Sodium Butyrate, Probiotics, and Short Chain Fructooligosaccharides in Patients with Irritable Bowel … doi:10.3390/jcm14010006 PubMed
- [12] Sylvia Cruchet Muñoz et al.. Nutrients. 2024. Effects of Bifidobacterium longum 35624 in Children and Adolescents with Irritable Bowel Syndrome. doi:10.3390/nu16121967 PubMed
- [13] S Srivastava et al.. Gut Microbes. 2024. A randomized double-blind, placebo-controlled trial to evaluate the safety and efficacy of live Bifidobacterium longum CECT 7347 (ES1) and heat-treated … doi:10.1080/19490976.2024.2338322 PubMed
- [14] Han Chen et al.. J Transl Med. 2023. Alternation of the gut microbiota in irritable bowel syndrome: an integrated analysis based on multicenter amplicon sequencing data. doi:10.1186/s12967-023-03953-7 PubMed
- [15] Xueli Jin et al.. Food Funct. 2023. Selenium-enriched Bifidobacterium longum DD98 relieves irritable bowel syndrome induced by chronic unpredictable mild stress in mice. doi:10.1039/d2fo03408e PubMed
- [16] David Groeger et al.. Neurogastroenterol Motil. 2023. Interactions between symptoms and psychological status in irritable bowel syndrome: An exploratory study of the impact of a probiotic combination. doi:10.1111/nmo.14477 PubMed
- [17] Xin-Hui Khoo et al.. J Gastroenterol Hepatol. 2023. The impact of diet and ethnicity on gut microbiota variation in irritable bowel syndrome: A multi-center study. doi:10.1111/jgh.16174 PubMed
- [18] O I Solovyeva et al.. Ter Arkh. 2023. [Long-term probiotic administration for irritable bowel syndrome: a legal need]. doi:10.26442/00403660.2023.08.202378 PubMed
- [19] V N Drozdov et al.. Vopr Pitan. 2023. [Clinical efficacy of a modern probiotic for the correction of intestinal microflora in patients with irritable bowel syndrome with diarrhea … doi:10.33029/0042-8833-2023-92-4-92-103 PubMed
- [20] Jean-Marc Sabaté et al.. World J Gastroenterol. 2022. Effect of Bifidobacterium longum 35624 on disease severity and quality of life in patients with irritable bowel syndrome. doi:10.3748/wjg.v28.i7.732 PubMed
- [21] Seung Yong Shin et al.. J Neurogastroenterol Motil. 2022. Compositional Changes in the Gut Microbiota of Responders and Non-responders to Probiotic Treatment Among Patients With Diarrhea-predominant Irritable Bowel Syndrome: … doi:10.5056/jnm21202 PubMed
- [22] Yae Jin Choi et al.. J Microbiol Biotechnol. 2022. Immunomodulatory Effects of Bifidobacterium spp. and Use of Bifidobacterium breve and Bifidobacterium longum on Acute Diarrhea in Children. doi:10.4014/jmb.2206.06023 PubMed
- [23] Yuya Nakamura et al.. Comput Struct Biotechnol J. 2022. Integrated gut microbiome and metabolome analyses identified fecal biomarkers for bowel movement regulation by Bifidobacterium longum BB536 supplementation: A RCT. doi:10.1016/j.csbj.2022.10.026 PubMed
- [24] Edgar Torres-Maravilla et al.. Sci Rep. 2022. Serpin-positive Bifidobacterium breve CNCM I-5644 improves intestinal permeability in two models of irritable bowel syndrome. doi:10.1038/s41598-022-21746-8 PubMed
- [25] E P Yakovenko et al.. Ter Arkh. 2022. [The effectiveness of a probiotic containing Bifidobacterium longum BB-46 and Enterococcus faecium ENCfa-68 in the treatment of post-infectious irritable bowel … doi:10.26442/00403660.2022.02.201368 PubMed
- [26] Luisa Marras et al.. Microorganisms. 2021. The Role of Bifidobacteria in Predictive and Preventive Medicine: A Focus on Eczema and Hypercholesterolemia. doi:10.3390/microorganisms9040836 PubMed
- [27] Cristina Iribarren et al.. Nutrients. 2021. The Effects of Human Milk Oligosaccharides on Gut Microbiota, Metabolite Profiles and Host Mucosal Response in Patients with Irritable Bowel … doi:10.3390/nu13113836 PubMed
- [28] Francesco Di Pierro et al.. Clin Nutr ESPEN. 2021. Bifidobacterium longum W11: Uniqueness and individual or combined clinical use in association with rifaximin. doi:10.1016/j.clnesp.2020.12.025 PubMed
- [29] E V Shikh et al.. Vopr Pitan. 2021. [Prospects of probiotic strains of bifidobacteria and enterococcus in treatment and prevention of diseases in gastroenterology]. doi:10.33029/0042-8833-2021-90-2-15-25 PubMed
- [30] Selina R Cox et al.. Gastroenterology. 2020. Effects of Low FODMAP Diet on Symptoms, Fecal Microbiome, and Markers of Inflammation in Patients With Quiescent Inflammatory Bowel Disease … doi:10.1053/j.gastro.2019.09.024 PubMed
- [31] Leonilde Bonfrate et al.. Eur J Clin Invest. 2020. Effects of Bifidobacterium longum BB536 and Lactobacillus rhamnosus HN001 in IBS patients. doi:10.1111/eci.13201 PubMed
- [32] Barbara Skrzydło-Radomańska et al.. Nutrients. 2020. The Effectiveness of Synbiotic Preparation Containing Lactobacillus and Bifidobacterium Probiotic Strains and Short Chain Fructooligosaccharides in Patients with Diarrhea Predominant … doi:10.3390/nu12071999 PubMed
- [33] Erin D Lewis et al.. Nutrients. 2020. Efficacy of Lactobacillus paracasei HA-196 and Bifidobacterium longum R0175 in Alleviating Symptoms of Irritable Bowel Syndrome (IBS): A Randomized, Placebo-Controlled … doi:10.3390/nu12041159 PubMed
- [34] Chunhua Zhou et al.. Gut Microbes. 2020. Bifidobacterium longum alleviates irritable bowel syndrome-related visceral hypersensitivity and microbiota dysbiosis via Paneth cell regulation. doi:10.1080/19490976.2020.1782156 PubMed
- [35] Gian Paolo Caviglia et al.. J Clin Med. 2020. Clinical Response and Changes of Cytokines and Zonulin Levels in Patients with Diarrhoea-Predominant Irritable Bowel Syndrome Treated with Bifidobacterium Longum … doi:10.3390/jcm9082353 PubMed
- [36] Berkeley N Limketkai et al.. Cochrane Database Syst Rev. 2020. Probiotics for induction of remission in Crohn's disease. doi:10.1002/14651858.CD006634.pub3 PubMed
- [37] Paola Vitellio et al.. Nutrients. 2019. Effects of Bifidobacterium longum and Lactobacillus rhamnosus on Gut Microbiota in Patients with Lactose Intolerance and Persisting Functional Gastrointestinal Symptoms: … doi:10.3390/nu11040886 PubMed
- [38] Z F Ma et al.. Benef Microbes. 2019. Bifidobacterium infantis M-63 improves mental health in victims with irritable bowel syndrome developed after a major flood disaster. doi:10.3920/BM2018.0008 PubMed
- [39] Afifa Ait-Belgnaoui et al.. J Neurogastroenterol Motil. 2018. Bifidobacterium longum and Lactobacillus helveticus Synergistically Suppress Stress-related Visceral Hypersensitivity Through Hypothalamic-Pituitary-Adrenal Axis Modulation. doi:10.5056/jnm16167 PubMed
- [40] Ya-Nan Cao et al.. Saudi J Gastroenterol. 2018. Lactobacillus acidophilus and Bifidobacterium longum supernatants upregulate the serotonin transporter expression in intestinal epithelial cells. doi:10.4103/sjg.SJG_333_17 PubMed
- [41] Carrie A M Wegh et al.. J Clin Gastroenterol. 2018. Effectiveness of Probiotics in Children With Functional Abdominal Pain Disorders and Functional Constipation: A Systematic Review. doi:10.1097/MCG.0000000000001054 PubMed
- [42] Chase Meyer et al.. Gastroenterology. 2018. The Fragility of Probiotic Bifidobacterium longum NCC3001 Use for Depression in Patients With Irritable Bowel Syndrome. doi:10.1053/j.gastro.2017.09.055 PubMed
- [43] Maria Ines Pinto-Sanchez et al.. Gastroenterology. 2017. Probiotic Bifidobacterium longum NCC3001 Reduces Depression Scores and Alters Brain Activity: A Pilot Study in Patients With Irritable Bowel Syndrome. doi:10.1053/j.gastro.2017.05.003 PubMed
- [44] Amy R Romijn et al.. Aust N Z J Psychiatry. 2017. A double-blind, randomized, placebo-controlled trial of Lactobacillus helveticus and Bifidobacterium longum for the symptoms of depression. doi:10.1177/0004867416686694 PubMed
- [45] Fuqiang Yuan et al.. Curr Med Res Opin. 2017. Efficacy of Bifidobacterium infantis 35624 in patients with irritable bowel syndrome: a meta-analysis. doi:10.1080/03007995.2017.1292230 PubMed
- [46] Emma P Halmos. J Gastroenterol Hepatol. 2017. When the low FODMAP diet does not work. doi:10.1111/jgh.13701 PubMed
- [47] Andrew P Allen et al.. Curr Med Res Opin. 2017. Bifidobacterium infantis 35624 and other probiotics in the management of irritable bowel syndrome. Strain specificity, symptoms, and mechanisms. doi:10.1080/03007995.2017.1322571 PubMed
- [48] Friedrich Altmann et al.. PLoS One. 2016. Genome Analysis and Characterisation of the Exopolysaccharide Produced by Bifidobacterium longum subsp. longum 35624™. doi:10.1371/journal.pone.0162983 PubMed
- [49] Qiao-Yan Gu et al.. Artif Cells Nanomed Biotechnol. 2016. Role of NLRP3 inflammasome in Bifidobacterium longum-regulated visceral hypersensitivity of postinfectious irritable bowel syndrome. doi:10.3109/21691401.2015.1111238 PubMed
- [50] Jun Sik Yoon et al.. J Gastroenterol Hepatol. 2014. Effect of multispecies probiotics on irritable bowel syndrome: a randomized, double-blind, placebo-controlled trial. doi:10.1111/jgh.12322 PubMed
- [51] János Fehér et al.. Orv Hetil. 2014. [Correlation of the microbiota and intestinal mucosa in the pathophysiology and treatment of irritable bowel, irritable eye, and irritable mind … doi:10.1556/OH.2014.29987 PubMed
- [52] María Ortiz-Lucas et al.. Rev Esp Enferm Dig. 2013. Effect of probiotic species on irritable bowel syndrome symptoms: A bring up to date meta-analysis. doi:10.4321/s1130-01082013000100005 PubMed
- [53] Bong Ki Cha et al.. J Clin Gastroenterol. 2012. The effect of a multispecies probiotic mixture on the symptoms and fecal microbiota in diarrhea-dominant irritable bowel syndrome: a randomized, … doi:10.1097/MCG.0b013e31823712b1 PubMed
- [54] Libera Fanigliulo et al.. Acta Biomed. 2006. Role of gut microflora and probiotic effects in the irritable bowel syndrome. PubMed
FDAに関する免責事項: これらの記述は米国食品医薬品局（FDA）による評価を受けていません。本ウェブサイトの製品および情報は、疾病の診断、治療、治癒、または予防を目的としたものではありません。表示されているエビデンスグレードは、公開された査読済み研究の分析に基づいており、医療上の助言を構成するものではありません。サプリメントの摂取を開始する前に、必ず医療専門家にご相談ください。